Mazdutide Dosage: Doses Studied, Units and Chart
What doses of Mazdutide have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 8 studies
- with a stated dose, listed below
- Frequency
- once weekly
- as used in studies
- Half-life
- Not found
- No published half-life found (PubMed search, 2 Oct 2026)
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| 9 mg vs placebo (2:1) | once weekly · subcutaneous · 60 weeks | Human RCTn = 461 | JAMA 2026, PMID 42251595 |
| 3-6 mg, 10 mg or 16 mg vs placebo | once weekly · subcutaneous · 48 weeks | Human RCTn = 179 | The lancet. Diabetes & endocrinology 2026, PMID 42628555 |
| 4 mg or 6 mg vs placebo | once weekly · subcutaneous · 24 weeks, then 24 weeks extended treatment | Human RCTn = 320 | Nature 2026, PMID 41407859 |
| 4 mg or 6 mg mazdutide vs dulaglutide 1.5 mg | once weekly · subcutaneous · 28 weeks | Human RCTn = 731 | Nature 2026, PMID 41407860 |
| 4 mg or 6 mg vs placebo | once weekly · subcutaneous · 48 weeks | Human RCTn = 610 | The New England journal of medicine 2025, PMID 40421736 |
| 3, 4.5 or 6 mg vs dulaglutide 1.5 mg or placebo | once weekly · subcutaneous · 20 weeks | Human RCT | Diabetes care 2024, PMID 37943529 |
| 3, 4.5 or 6 mg vs placebo | once weekly · subcutaneous · 24 weeks | Human RCTn = 248 | Nature communications 2023, PMID 38092790 |
| IBI362 (mazdutide) 3.0, 4.5 or 6.0 mg vs placebo (2:1) | once weekly · subcutaneous · 12 weeks | Human RCT | EClinicalMedicine 2021, PMID 34430840 |
Before anyone considers it
- Mazdutide is investigational and not approved for any use.
- Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
Dose arms across the Chinese phase 2 and 3 trials
The phase 2 trial compared mazdutide 3 mg, 4.5 mg and 6 mg weekly with placebo for 24 weeks. Mean weight change was -6.7%, -10.4% and -11.3% respectively, against 1.0% on placebo.[9]
The phase 3 GLORY-1 trial compared 4 mg and 6 mg with placebo for 48 weeks.[7]
GLORY-2 tested a higher once-weekly 9 mg dose against placebo for 60 weeks.[3]
Discontinuations by arm
Adverse events led to discontinuation in 1.5% on 4 mg, 0.5% on 6 mg and 1.0% on placebo in GLORY-1.[7]
In GLORY-2, 2.9% discontinued for adverse events versus 0% on placebo, with vomiting in 53.1%.[3]
No FDA-approved mazdutide product exists, so these are trial designs from China rather than a US label.[14]
Common questions
Is Mazdutide FDA approved?
No. Mazdutide is investigational (investigational in the us (approved in china)) and not approved for any use.
What is the mazdutide dosage in trials?
Phase 3 arms were 4 mg and 6 mg once weekly for 48 weeks, plus a higher-dose arm in a separate trial.[7]
What is the mazdutide starting dose?
The phase 2 abstract lists 3 mg as its lowest arm; it does not describe a starting dose or titration step.[9]
More on Mazdutide
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.JAMA · 2026PMID 42251595Accessed 2 Oct 2026
- 4Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.The lancet. Diabetes & endocrinology · 2026PMID 42628555Accessed 2 Oct 2026
- 5Mazdutide versus placebo in Chinese adults with type 2 diabetes.Nature · 2026PMID 41407859Accessed 2 Oct 2026
- 6Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.Nature · 2026PMID 41407860Accessed 2 Oct 2026
- 7Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.The New England journal of medicine · 2025PMID 40421736Accessed 2 Oct 2026
- 8Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.Diabetes care · 2024PMID 37943529Accessed 2 Oct 2026
- 9A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.Nature communications · 2023PMID 38092790Accessed 2 Oct 2026
- 10IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.EClinicalMedicine · 2021PMID 34430840Accessed 2 Oct 2026
- 11PubMed search: mazdutide[tiab] OR IBI362[tiab] OR LY3305677[tiab] (53 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: (mazdutide[tiab] OR IBI362[tiab] OR LY3305677[tiab]) AND (randomized[tiab] OR trial[tiab] OR phase[tiab]) (31 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: (mazdutide[tiab] OR IBI362[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (1 result)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14Drugs@FDA (openFDA) search: active ingredient "mazdutide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.